… phase 2 trial of bevacizumab in recurrent glioblastoma. … the bevacizumab plus lomustine 90
mg/m 2 combination warrants … single-agent bevacizumab in recurrent glioblastoma seems to …

… II trial of patients with recurrent glioblastoma, BV in combination with CPT-11 … in combination
with CPT-11 in patients with glioblastoma who were experiencing first or second relapse …

… Therefore, the combination of bevacizumab and temsirolimus was explored in this study,
despite modest activity with mTOR inhibitors in recurrent glioma (10, 16). Combinations of …

… for bevacizumab's benefit on recurrent glioblastomas and to analyze its dose–response effect.
… in combination with bevacizumab, whereas 2 used bevacizumab alone and 1 combined …

… Another Phase II study has been conducted by the Italian Association of Neuro-Oncology
using another nitrosourea, fotemustine, in combination with bevacizumab in recurrent GBM […

… study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed
with VB-111 monotherapy that was continued after progression with concomitant bevacizumab. …

… We retrospectively screened our databases for patients with recurrent glioblastoma treated
with BEV alone or in combination with irinotecan (IRI) between January 2008 and December …

… Conclusions: This is the first study to report safety/tolerability of combination PD-1 plus
VEGF blockade in GBM. P and Bev were safely combined when administered according to …

… Background: Glioblastoma is characterized by rich vasculature and abnormal vascular …
Currently, there is no standard treatment for recurrent glioblastoma (rGBM). Bevacizumab (BEV) …

… While most studies in recurrent GBM have evaluated bevacizumab (in combination with
irinotecan) on a schedule of 10 mg/kg every 2 weeks or a weekly equivalent dose of 15 mg/kg …